BRISBANE, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced that Todd Whitson will join CareDx as the Chief Commercial Officer.
Todd Whitson brings over 15 years of healthcare sales experience in both genetics and molecular diagnostics. As Vice President of Sales at Genzyme Genetics he helped to drive the success of the company that eventually led to an acquisition by LabCorp. He was then asked to lead up the combined, integrated oncology business unit across all of LabCorp.
Todd most recently served as the Vice President of Commercial Operations at Ariosa Diagnostics, which is now part of the Roche Group. Todd was the first commercial hire at Ariosa and built the organization from a small, private company to a leader in the field of Non-Invasive Prenatal Testing (NIPT) based on cell-free DNA technology and next-generation sequencing.
“My colleagues and I are excited that Todd Whitson is joining our team at CareDx,” said Peter Maag, President and Chief Executive Officer of CareDx. “Todd brings significant experience in diagnostics, specifically in the launch and growth of innovative products and technologies.”
"I look forward to joining CareDx to drive the uptake of AlloMap and prepare for the impending launch of AlloSure,” said Mr. Whitson. “CareDx represents a unique opportunity to join a well established company that will be introducing a revolutionary approach to transplant surveillance in the near future.”
Todd Whitson will join CareDx the week of April 18, 2016.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. For more information, please visit: www.CareDx.com.
Forward Looking Statements
In addition to the historical information, this press release contains forward-looking statements with respect to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks related to our development of AlloSure and ability to commercialize a new test. These factors, together with those that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed by us with the SEC on March 31, 2015, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our results for the most recent reporting period are not necessarily indicative of our operating results for any future periods.
Media Contacts – CareDx Molly Martell, Senior Director, Marketing T: +1 415-728-6307 E: firstname.lastname@example.org Media Contacts - Investor Jamar Ismail, Vice President Westwicke Partners, LLC T: +1 415-513-1282 E: email@example.com